{'fraction_non_alphanumeric': 0.06431718061674009, 'fraction_numerical': 0.06255506607929516, 'mean_word_length': 5.454545454545454, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effect of histamine‐H1 receptor antagonism with terfenadine on concentration‐related AMP‐induced bronchoconstriction in asthma

Selective histamine‐H1 receptor antagonists inhibit adenosine 5′‐monophosphate (AMP)‐induced bronchoconstriction by > 80% when expressed as a percentage inhibition of the FEV1 time–response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20). To investigate this further we have determined that, in eight mild atopic asthmatic subjects, terfenadine (180 mg), administered 3 hr pre‐challenge, increases the geometric mean PC20 for histamine from 0.4 (range 0.03–3) mg/ml after placebo, to 20.2 (range 0.6–64) mg/ml following active treatment (P<0.0001). For AMP, the PC20 increased from 9.3 (range 1.0–113.3) mg/ml after placebo, to 150.2 (range 32.1–1177.7) mg/ml with terfenadine (P<0.0001). This 16.2‐fold (range, 5.5–47.9) displacement to the right of the AMP concentration–response curve by a selective histamine‐H1 receptor antagonist emphasizes the central role of histamine in the airways response to this nucleotide.